|
1. |
Therapy of Acute Stroke |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 91-120
Conrado Estol,
Louis Caplan,
Preview
|
PDF (2033KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
2. |
Convulsive DisordersMechanisms of Epilepsy and Anticonvulsant Action |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 121-128
Thomas Bleck,
Harold Klawans,
Preview
|
PDF (470KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
3. |
The Role of the Blood–Brain Barrier in Movement Disorders |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 129-146
Nina Paleologos,
Dennis Groothuis,
Preview
|
PDF (1144KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
4. |
Neuropsychological Effects of L‐Deprenyl in Alzheimer's Type Dementia |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 147-163
Gian Piccinin,
Giancarlo Finali,
Massimo Piccirilli,
Preview
|
PDF (987KB)
|
|
摘要:
The monoaminergic neurotransmission defect seen in dementia of the Alzeheimer type (DAT) is linked to a known increased activity of type B cerebral monoamine oxidases (MAO-Bs). The use of drugs that are able to block this abnormal activity could therefore be useful in the treatment of some cognitive deficits that characterize DAT. Twenty patients with a clinical diagnosis of DAT and with a slight-moderate mental deterioration were treated with 10 mg/day of L-deprenyl, a selective MAO-B inhibitor, according to a double-blind crossover design vs. placebo. Initial treatment (drug or placebo) was randomly assigned. The patients' cognitive functions were evaluated at baseline and then after 3 and 6 months of treatment with drug or placebo. The patients crossed over treatment after 3 months, without a washout interval. The results of the study show the higher and statistically significant effects of L-deprenyl on memory and attention that seem to be due to an improved function of the monoaminergic systems involved in the process of neuronal degeneration.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
5. |
Complex Dystonia of Parkinson's DiseaseClinical Features and Relation to Plasma Levodopa Profile |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 164-170
Denise McHale,
Jacob Sage,
Patricia Sonsalla,
Dawn Vitagliano,
Preview
|
PDF (393KB)
|
|
摘要:
We studied the clinical characteristics and plasma levodopa (LD) profile of complex, LD-associated dystonia in 33 patients with Parkinson's disease (PD). Generalized, abdominal, respiratory, and myoclonic, but not facial or foot, dystonia could be related to specific phases of the plasma LD cycle. Simultaneous clinical observation and determinations of plasma LD concentrations were often necessary to find the most efficacious dosing schedule for these patients. Maintenance of steady plasma LD concentrations within a dystonia-free window of benefit was the best treatment.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
6. |
Evidence for the Role of Spinal Cord Systems in Parkinson's Disease‐Associated Pain |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 171-174
J. Sage,
H. Kortis,
W. Sommer,
Preview
|
PDF (239KB)
|
|
摘要:
A patient with Parkinson's disease had severe levodopa-associated leg pain in a beginning-of-dose and peak-dose pattern. Local anesthetic block of the lumbar sympathetic chain or differential epidural block did not alter the pain. Spinal anesthesia abolished the pain. We postulate that levodopa-associated pain in Parkinson's disease either originates in or is mediated by spinal cord dopaminergic systems.
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
7. |
Neurologic Clinics |
|
Clinical Neuropharmacology,
Volume 13,
Issue 2,
1990,
Page 175-175
R. Portenoy,
Angela Mailis,
Preview
|
PDF (83KB)
|
|
ISSN:0362-5664
出版商:OVID
年代:1990
数据来源: OVID
|
|